BiotechTube

Tipifarnib + Alpelisib

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HNSCC

Conditions

HNSCC

Trial Timeline

Dec 7, 2021 → Jul 30, 2025

NCT ID
NCT04997902

About Tipifarnib + Alpelisib

Tipifarnib + Alpelisib is a phase 1/2 stage product being developed by Kura Oncology for HNSCC. The current trial status is completed. This product is registered under clinical trial identifier NCT04997902. Target conditions include HNSCC.

What happened to similar drugs?

0 of 2 similar drugs in HNSCC were approved

Approved (0) Terminated (1) Active (1)
🔄Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
❌LymphoseekNavidea BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04997902Phase 1/2Completed

Competing Products

18 competing products in HNSCC

See all competitors
ProductCompanyStageHype Score
AZD2936AstraZenecaPhase 2
42
pepinemab + pembrolizumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
39
Pembrolizumab, CetuximabMerckPhase 2
35
eftilagimod alpha + pembrolizumab (KEYTRUDA®)MerckPhase 2
35
Cetuximab/avelumabMerckPhase 2
42
Ulevostinag + PembrolizumabMerckPhase 2
35
Motolimod + NivolumabBristol Myers SquibbPhase 1
21
Nivolumab + Cisplatin + CetuximabBristol Myers SquibbPhase 1
29
Nivolumab + Relatlimab + IpilimumabBristol Myers SquibbPhase 2
42
Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
47
FDC fianlimab+cemiplimab + Cemiplimab + PlaceboRegeneron PharmaceuticalsPhase 2
42
GTAEXS617 + SoCRecursion PharmaceuticalsPhase 1/2
33
Ficerafusp alfa + PembrolizumabBicara TherapeuticsPhase 2
36
INBRX-106 + PembrolizumabInhibrx BiosciencesPhase 2/3
39
STRO-004 + PembrolizumabSutro BiopharmaPhase 1
26
DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2Phio PharmaceuticalsPhase 1
23
LymphoseekNavidea BiopharmaceuticalsPhase 3
22